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The objective of this paper was to analyze the data supporting the possible role of melatonin on bone metabolism and its
repercussion in the etiology and treatment of bone pathologies such as the osteoporosis and the adolescent idiopathic scoliosis
(AIS). Melatonin may prevent bone degradation and promote bone formation through mechanisms involving both melatonin
receptor-mediatedandreceptor-independentactions.Thethreeprincipalmechanismsofmelatonineﬀectsonbonefunctioncould
be:(a)thepromotionoftheosteoblastdiﬀerentiationandactivity;(b)anincreaseintheosteoprotegerinexpressionbyosteoblasts,
thereby preventing the diﬀerentiation of osteoclasts; (c) scavenging of free radicals generated by osteoclast activity and responsible
for bone resorption. A variety of in vitro and in vivo experimental studies, although with some controversial results, point toward
a possible role of melatonin deﬁcits in the etiology of osteoporosis and AIS and open a new ﬁeld related to the possible therapeutic
use of melatonin in these bone diseases.
1.Introduction
Bones are structures under a continuous process of remod-
elating by the coupled activity of cells with resorptive
functions (osteoclasts) and cells responsible for the for-
mation of new bone (osteoblasts). The balance between
the activities of both cell types is under the control of
systemic hormones including parathyroid hormone (PTH),
estradiol (E2), and growth hormone as well as of cytokines
and growth factors produced in the bone marrow [1]. A
major disease of bone, osteoporosis, has been deﬁned as “a
systemic disease characterized by low bone mass and micro
architectural deterioration of bone tissue, with consequent
increase in bone fragility and susceptibility to fracture”. This
is a disease predominantly associated with aging, with a
special prevalence among women [2]. Adolescent idiopathic
scoliosis (AIS) is the most common type of scoliosis and
also is more prevalent among females, especially during
prepuberal and puberal growth, when bone acquisition is
highest [3].
Melatonin is an indoleamine secreted primarily by the
pineal gland but also synthesized in other organs such as
retina, gastrointestinal tract, and bone marrow. Melatonin
plays a regulatory role in many physiological processes
including bone physiology [4–10]. Nocturnal plasma mela-
tonin levels signiﬁcantly decline after the age of 50 in both
genders [11, 12]. Since the time course of the reduction
of melatonin production and the progression of bone
deteriorationruninparallel,thepossibleroleofmelatoninin
osteoporosis has been considered worthy of study. Regarding
AIS, the fact that experimental pinealectomy in diﬀerent
animal models [13–22] results in scoliosis which closely
resembles the human pathology opened a new ﬁeld of
research on the role of melatonin in the AIS.
The objectives of the current paper are (a) to review
the data supporting the possible role of the age-dependent
decrease of melatonin in the development of osteoporosis
and the therapeutic value of melatonin as a treatment for
this disease, and (b) to analyze the evidence related to the
role of melatonin in the etiology and treatment of the AIS.2 Journal of Osteoporosis
Before doing so, we will describe the eﬀects of melatonin on
bone physiology, as the basis to understand the participation
of this indoleamine in bone pathology.
2.MelatoninandBonePhysiology
The eﬀects of melatonin on bone physiology were reviewed
in an excellent article by Cardinali et al. [4]. The possible
inﬂuence of melatonin on bone metabolism was repeatedly
proposed by diﬀerent authors during the last four decades
[23–27]. These proposals were made on the basis of evidence
for the pineal control of the secretion of parathyroid
hormoneandcalcitonin,demonstrablebytheultrastructural
and functional changes observed in parathyroid glands
after pinealectomy. The earliest experiments examined the
inﬂuence of the pineal on calcemia. It was observed, for
example, that the inhibition of melatonin synthesis by
exposure of newborn rats to white ﬂuorescent light reduced
the concentration of calcium in the serum [28]. This
eﬀectwaspreventedbyexogenousmelatoninadministration.
Light-induced hypocalcemia may result from augmented
calcium uptake by bone when melatonin levels are reduced
after inhibition of its synthesis by light [28]. Likewise,
when melatonin secretion was inhibited in rats by the
administration of β-adrenoceptor blockers, serum concen-
trations of calcium dropped [29]a ne ﬀect which was
also prevented by the administration of melatonin. The
conclusion from these experiments is that suppression of
melatonin causes hypocalcemia and additionally suggesting
thatmelatoninwouldnormallyupregulatethebloodlevelsof
calcium.
More recently, Ostrowska et al. [30] re-examined, in
male rats, the eﬀects of the exposure to diﬀerent lighting
conditionsnotonlyoncalcemiabutalsoonbonephysiology.
They did this by evaluating the inﬂuence of alterations
in the light:dark cycle on biochemical markers of bone
metabolism (serum alkaline phosphatase, concentration of
carboxyterminal propeptide of type I procollagen, cross-
linked carboxyterminal telopeptide of type I collagen, inor-
ganic phosphorus, urinary excretion of hydroxyproline and
calcium). They reported that short days (LD 0.5:23.5 h)
had a stimulatory eﬀect on the level of these markers,
while exposure to long days (LD 23.5:0.5 h) was inhibitory.
Anomalies in daily oscillations of these markers with a
negative correlation with the changes in endogenous mela-
tonin concentrations and a positive correlation with daily
ﬂuctuations of IGF-I and triiodothyronine (T3) were also
described. These results led the authors to conclude that
lighting conditions inﬂuence bone metabolism in rats, and
that melatonin likely plays an important role in these
photoperiodic eﬀects. Secondary changes in daily IGF-I and
T3 oscillations, caused by short- and long-day conditions,
also result in altered rhythmicity of daily bone resorption
[30]. This experiment demonstrated the possible inﬂuence
of melatonin on bone metabolism but not its concrete eﬀects
on bone formation and resorption. However, positive eﬀects
of melatonin on osteoblastic activity were deduced from the
increases in the formation of cortical bone in mice treated
with intraperitoneal injections of the indoleamine [31].
One interesting ﬁnding potentially related to melatonin
and bone health is the demonstration of high concentra-
tions of melatonin in bone marrow cells from mice and
humans [32, 33], with the concentrations being approx-
imately twice as high as nighttime levels in peripheral
blood [32]. The cells in question contain aryl-alkyl-N-
acetyltransferase activity and express the mRNA encoding
hydroxyindole-O-methyltransferase, indicating the ability of
the cells to synthesize melatonin de novo [33]. Moreover,
human osteoblasts express MT1 melatonin receptors, and its
expression level decreases with the age of the host [31]. The
presence of melatonin in bone marrow may be protective
against oxidative damage in the proliferating hematopoietic
cells or involved in bone development through osteoblast
diﬀerentiation [34, 35].
A variety of in vitro studies support the hypothesis
of stimulatory eﬀects of melatonin on both osteoblast
diﬀerentiation and activity. Preosteoblasts cultured in the
presence of melatonin underwent early cell diﬀerentiation
andamajorexpressionofbonemarkerproteinscomparedto
control cells incubated without melatonin [36]. These eﬀects
are prevented by the melatonin receptor antagonist luzindole
[36]. The age-related decrease of melatonin production
could shift the bone marrow cells diﬀerentiation from
osteoblastic diﬀerentiation toward an adipocytic line of
cell, which could explain the development of osteoporosis
during aging [37]. Melatonin also promotes the osteogenic
diﬀerentiation of bone marrow stem cells whereas it has
negative eﬀects on diﬀerentiation of adipose-derived stem
cells [38, 39].
In cultures of human osteoblasts [31, 40], melatonin,
at pharmacological doses (μM range), (a) stimulates the
proliferation and alkaline phosphatase activity of these cells;
(b) promotes the expression of type I collagen, osteopon-
tin, bone sialoprotein, and osteocalcin; (c) stimulates the
formation of mineralized matrix. The signaling mechanisms
mediating the melatonin actions on osteoblasts are still
unknown although the role of the MAPK pathway seems
relevant [35].
The activity of osteoclasts is under the control of
paracrine factors produced by the osteoblasts. PTH and
1,25-dihydroxycholecalcipherol stimulate the expression of
an osteoclast diﬀerentiating factor (ODF) by the marrow
stromal cells and osteoblasts. ODF binds to the receptor
activator of nuclear factor-κB (RANK) on the surface of
the osteoclast activating bone resorption [4, 41]. In mouse
osteoblasts, melatonin, at micromolar doses, decreases the
expression of RANK mRNA and increases both the mRNA
and protein levels of osteoprotegerin, a member of the
s u p e rf a m i l yo fT N F R( t u m o rn e c r o s i sf a c t o rr e c e p t o r )
which inhibits the diﬀerentiation of osteoclasts by binding
to ODF and preventing the binding of this factor to
RANK [42]. Via this mechanism, melatonin could cause
an inhibition of bone resorption and an increase in bone
mass.
One important component of the osteoclasts activity
is the generation of free radicals which contribute to the
process of bone degradation and resorption [43]. Melatonin,
due to its ability to directly neutralize free radicals and toJournal of Osteoporosis 3
stimulate the activity of antioxidative enzymes [44, 45], may
reduce osteoclastic activity.
Figure 1 summarizes the principal mechanisms reviewed
above related to melatonin’s eﬀects on bone function.
These actions include: (a) the promotion of the osteoblastic
diﬀerentiation, activity and expression of osteoprotegerin
which prevents the diﬀerentiation of osteoclasts, and (b)
scavenging of free radicals generated by osteoclastic activity
and responsible for bone resorption.
Thereare,however,datacontrarytothehypothesisofthe
eﬀect of melatonin on bone-forming osteoblasts. Ostrowska
et al. [46] found, in male Wistar rats, that high plasma
concentrations of melatonin correlated with low levels of
bone forming markers, and that pinealectomy elevated the
levels of bone metabolism biomarkers and altered the phase
and amplitude of its circadian rhythm. In another interesting
study, Suzuki and Hattori [47] cultured osteoblasts in the
presence of osteoclasts, analyzing the eﬀects of melatonin
on both, that is, osteoblastic and osteoclastic activity, by
the changes on speciﬁc biomarkers in each cell type. They
observed an inhibition by melatonin of the activity of
both cell types. These authors emphasize the importance
of the cell-to-cell interactions between osteoblasts and
osteoclasts to understand their physiologic function as well
as in the response to melatonin. Since melatonin inhibits
both osteoblasts and osteoclasts, the ﬁnal outcome of their
eﬀects could be the balance between the actions of these
cellular elements. In postmenopausal women, bone resorp-
tion increases more than bone formation, thus resorption
becomes the major determinant of bone mass [48]; in these
cases, even therapies like melatonin, that may inhibit both
osteoclasts and osteoblasts activity, should have positive
eﬀects on bone mass.
An interesting question is the interaction of melatonin
with estrogens at the level of the osteoblast. Estrogens have a
positive impact on bone growth. Melatonin, according to the
studies summarized above, has similar eﬀects. Under many
other circumstances, however, estrogens and melatonin
usually have opposing eﬀects. Thus, it is well known that
estradiol modulates the function of the melatonin receptors
in rat ovary [49] and Chinese hamster ovary cells [50], and
that melatonin suppresses transcriptional activation of the
ERα in MCF-7 cells by mechanisms involving calmodulin
[51–53]. A study in goldﬁsh scales showed that melatonin
suppresses the activity of osteoblasts by downregulating the
ER [47]; however, melatonin seems to enhance the eﬀects of
estradiol in the prevention of bone loss in ovariectomized
rats [54]. The nature of the interactions of estradiol with
melatonin on bone could be dependent of the estrogen con-
centration. In the above mentioned experiment, the preven-
tion of the postovariectomy disruption of bone remodeling
with pharmacological doses of melatonin required adequate
concentrations of estradiol.
3. Melatonin andOsteoporosis
Osteoporosis is a prolonged structural deterioration of
the skeletal system, usually associated with age, and with
a major prevalence in women. Antiosteoporosis therapies
include the use bisphosphonates, estrogen, and calcitonin to
inhibit bone-resorbing osteoclasts preventing further bone
breakdown. However, these therapies are insuﬃcient in cases
of individuals suﬀering from severe osteoporosis. Drugs that
stimulate bone-forming osteoblasts (e.g., teriparatide) are
expensive and with important associated side eﬀects [5].
These facts and the above described eﬀects of melatonin on
bone physiology prompted studies on their possible utility
as a complementary therapy for osteoporosis. Melatonin
has been shown at the cell and tissue levels to promote
osteogenesis and prevent bone deterioration in mammals
[55], birds [56, 57], and ﬁshes [21].
At present, no clinical trials have focused on the
possible therapeutic value of melatonin in the treatment
of osteoporosis. Some epidemiologic studies re-enforce the
possible etiologic role of melatonin in osteoporosis. This
is the case from a recent study of Feskanich et al. [58].
This group reported that in a sample of more than 38,000
postmenopausal women, compared with women who never
worked night shifts, twenty or more years of night shift work
signiﬁcantly increased the risk of wrist and hip fractures
over 8-year follow-up period. Night shift work causes
disturbances in the patterns of melatonin secretion as well
as severe circadian rhythm disruption [59].
Experimental studies carried out mostly in ovariec-
tomizedrats(asamodelofmenopause)suggest,ingeneral,a
protective role of melatonin in preventing bone degradation
and promoting bone formation most probably through an
action that involves melatonin receptors [4, 5]. Among
these studies are those of Oktem et al. [60], suggesting
that melatonin’s prevention of osteoporosis could be related
with its ability to inhibit inducible nitric oxide synthase
(iNOS). iNOS plays a critical role in the pathogenesis
of osteoporosis since it promotes the generation of nitric
oxide, a free radical which contributes to bone resorption
caused by estrogen depletion. By using the ovariectomized
rat as a model, these authors demonstrated that melatonin
treatment markedly reduced the expression of iNOS and
the number of apoptotic cells in nucleus pulposus and
epiphyseal cartilage of the spinal column, which increased
after ovariectomy. Using the same animal model, Uslu et al.
[61] described how trabecular thickness and trabecular area
of vertebra and femur and cortical thickness of femur, which
were signiﬁcantly reduced after ovariectomy, increased after
treatment with melatonin. Recently, Suzuki et al. [62, 63]
developed a synthetic melatonin derivative, 1-benzyl-2,4,6-
tribromomelatonin (bromomelatonin) which augmented
the total bone mineral density of ovariectomized rats more
eﬃciently than melatonin, suggesting its potential use in the
treatment of osteoporosis.
4.MelatoninandAdolescent Idiopathic
Scoliosis (AIS)
Although the etiology of the AIS is unclear, histomorpho-
metric data on iliac crest biopsies and vertebrae of scoliosis
patients showed an impaired function of both osteoblasts
andosteoclasts[64,65].Thepersistentosteopeniainpatients
with AIS [64–66] and the eﬀects of melatonin in bone4 Journal of Osteoporosis
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Figure 1: Eﬀects of melatonin on bone metabolism. (a) Melatonin promotes the osteoblast proliferation and the synthesis osteoprotegerin,
which inhibits the diﬀerentiation of osteoclasts by preventing the binding of ODF (osteoclast diﬀerentiation factor) to RANK on the
diﬀerentiating osteoclasts. (b) Melatonin through its free radical scavenging properties impairs osteoclast activity on bone. Based on
Cardinali et al. [4].
metabolism stimulated several studies in animal models
and humans related to the possible relationship between
melatonin deﬁcits and scoliosis [18, 19, 67–72].
The neuroendocrine hypothesis involving a melatonin
deﬁciency as the source for AIS has generated great interest
and controversy. This hypothesis, represented in Figure 2
(modiﬁed from Moreau et al. [73]), stems from the fact that
experimental pinealectomy in the chicken [13, 14, 18–20,
74, 75], rats, and mice with genetic deﬁciency of melatonin
forced into a bipedal mode of locomotion [16, 17, 22, 76],
rabbits [77], and Atlantic salmon [21] results in scoliosis
that closely resembles the AIS. Pinealectomy in chickens
induceshistomorphometricchangesinthevertebralcolumn.
In particular, the loss of melatonin induces a scoliotic
curvature and reduces mean weight and length of cervical
vertebrae, possibly due to a reduction in the total number
of osteocytes. These results were interpreted to mean that
melatonin may act to enhance osteocyte proliferation in the
cervical vertebrae [57].
Inbipedalpinealectomizedratsareductioninmelatonin,
as a consequence of the pineal ablation, was found to cause
scoliosis [14]. Recently, the possible role of calmodulin
(CaM) as a mediator of the melatonin antiscoliosis eﬀects
has been proposed [78–80]. Melatonin is an inhibitor of
calmodulin [81, 82] and, the loss of this inhibition, due
to the lack of melatonin, could be the cause of scoliosis in
these animal models. Since tamoxifen is working not only
through estrogen receptor but act also as a CaM antagonist,
pinealectomized chickens were treated with tamoxifen, and
the incidence of scoliosis decreased, presumably due to CaM
antagonism of this drug, although measures of CaM activity
were not made. In a similar study, carried out on C57BL6
mice (which are genetically melatonin deﬁcient), it was
observed that they develop scoliosis when rendered bipedal;
in these animals as well, tamoxifen improved the scoliosis
deformities. In humans, Acaroglu et al. [78] compared the
content of CaM and melatonin in muscle and platelets of
scolioticandhealthypopulations.Thepatientssuﬀeringwith
AIS had asymmetric distribution of CaM in the paraspinal
muscles, with its concentration being higher at the convex
side and lower at the concave curvatures of the spinal
column,whereasneitherplateletmelatoninnorplateletCaM
was found to be representative of the muscle protein values.
Not all data support the hypothesis of the reduction
of melatonin as the cause of scoliosis. Melatonin therapy
after pinealectomy in young chickens had no eﬀect on the
development or progression of scoliosis [83], and cutting of
the pineal stalk of the chicken, without removal of the pineal
gland, also resulted in scoliosis, whereas suppression of
melatonin secretion by exposure of the chickens to constant
light did not induce spinal curvature [84]. This suggests that
the cause of the scoliosis is more related with the surgery
than with the changes in melatonin secretion. Furthermore,
although melatonin receptors are present in the spinal cord
of the chicken, the changes detected in melatonin receptor
binding after pinealectomy cannot explain why scoliosis
develops in some chickens after pinealectomy, while it does
not in others [85].
Bipedal ambulation in mammals is required, associated
to low levels of melatonin, to generate scoliosis [22, 86]. The
disturbance of equilibrium and other postural mechanisms
secondary to a deﬁciency of melatonin may promote devel-
opment of lordoscoliosis with vertebral rotation especially in
the bipedal posture [86]. However, pinealectomized young
rhesus monkeys (8–11 months old) do not develop scoliosis.
This fact suggests that the possible etiologic factors produc-
ing idiopathic scoliosis in lower animals may be diﬀerent
from primate, and ﬁndings in birds and rodents cannot
necessarily be extrapolated to human beings [87, 88]. Since
monkeysincaptivity,placedincagesthatgreatlyrestricttheirJournal of Osteoporosis 5
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Figure 2: Summary of the experiments focused on the hypothesis involving a melatonin deﬁciency as the source for AIS. Eﬀective (green
lines) and noneﬀective (red lines) results are indicated. Modiﬁed from Moreau et al. [73].
mobility, spend most time in quadrupedal position, whether
or not posture and gravity are determinants in the response
to pinealectomy in terms of scoliosis is still unclear.
In humans, the question of the possible role of melatonin
in scoliosis has been addressed using diﬀerent analytical
approaches (see Figure 3, modiﬁed from Moreau et al. [73]).
One of these approaches was the detection of the possible
changes in melatonin production in scoliotic patients. In this
regard, Sadat-Ali et al. [89] found serum melatonin levels
signiﬁcantly lower in AIS patients than in healthy controls
these results support the hypothesis that serum melatonin
levels may contribute to the pathogenesis of idiopathic
scoliosis. However, no signiﬁcant diﬀerence between patients
with AIS and controls regarding in serum concentration
of melatonin or levels of urinary excretion of 6-sulfatoxy-
melatonin was found by other authors; they concluded that
a permanent melatonin deﬁciency is not a causative factor in
the etiology of AIE in humans [67, 71, 90–92].
Genetic studies have screened AID and healthy patients
looking for gene variants or single nuclear polymorphism in
genes involved in the control of melatonin synthesis or in the
expression of melatonin receptors. The screening of the MT2
receptor gene polymorphism in AIS patients and controls
[93] suggests that this is a gene involved in the predisposition
for AIS. However, the promoter polymorphism of the MT1
genewasnotassociatedwiththeoccurrenceorcurveseverity
of AIS, thus, indicating that MT1 gene may not be involved
in the etiopathogenesis of AIS [94]. Polymorphisms of the
arylalkylamine N-acetyltransferase (AANAT) gene were not
associated with AIS whereas single nuclear polymorphism of
tryptophan hydroxylase 1 gene (TPH1) seems closely related
withthedysfunctionofmelatonininAIS[95].Otherauthors
did not observe mutations in the coding region of the gene
for human melatonin receptor in patients with familiar AIS
[96].
A third category of studies have focused on the possible
changes in melatonin receptors in AIS patients. The expres-
sion of MT2 melatonin receptors in bilateral paravertebral
muscles in AIS and congenital scoliosis is asymmetric, being
higher in muscles on concave side than that on convex
side of the spinal column in AIS, but MT1 expression was
not signiﬁcantly diﬀerent [97, 98]. These diﬀerences in the
expression of melatonin receptors have been considered as
secondary to the bilateral asymmetry due to force exerted on
the scoliotic spine and not important in the pathogenesis of
AIS [97, 98].
Ad i ﬀerent and interesting approach presented by
Moreau et al. [99] could clarify the discrepancies regarding
the role of melatonin in AIS. These authors consider that
instead of changes in melatonin production or expression
of melatonin receptors, the problem may be in the speciﬁc
response of the osteoblast to melatonin in AIS patients. They
demonstrated a melatonin signaling dysfunction occurring
in osteoblasts isolated from AIS patients but not in similar
cells isolated from healthy subjects. In most cells, melatonin
inhibitstheforskolin-stimulatedadenylylcyclaseactivityand
decreases cAMP. In contrast, osteoblasts from patients with
AISshowedalackoramarkedinhibitionbymelatoninofthe
forskolin-stimulated adenylyl cyclase activity [99]. The cause
is an increased phosphorylation of serine residues aﬀecting
theactivityofG-inhibitoryproteinsnormallyassociatedwith
melatonin surface receptors [99]. In response to estradiol,
osteoblasts from a speciﬁc group of AIS patients treated with
melatonin decreased the cAMP abnormally increased by the
indoleamine [100]. From the ﬁndings of Moreau et al. [99],
a preliminary molecular classiﬁcation of AIS patients based
on the cellular response to melatonin (changes in cAMP),
has been proposed [101]. Recently, the same group [73]
have developed the ﬁrst blood test to detect children without
symptoms who are at risk of developing scoliosis. This test6 Journal of Osteoporosis
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Figure 3: Summary of the main experimental approaches carried out in humans to clarify the role of melatonin on the AIS. Left, (doted
rectangle), studies of changes in melatonin production. Yellow labels are the screening of polymorphisms in genes related with pineal
function. White labels identify studies of possible changes in melatonin metabolism or response of target tissues. As in Figure 2,e ﬀective
(green lines) and noneﬀective (red lines) results are indicated. Modiﬁed from Moreau et al. [73].
is based on the cellular reaction to melatonin. The most
recent clinical study on the relationship between melatonin
and AIS has been a prospective analysis on the correlation
of serum melatonin levels (monitored yearly for 3–6 years)
and curve progression in 40 patient with moderate to severe
AIS [102]. From 22 patients with normal melatonin levels
(similar to healthy age-matched controls), 16 had stable
scoliosis whereas 6 had progressive scoliosis. The 16 patients
with low melatonin levels were treated with oral melatonin
(3.0mg 1.5–2.0 hour before the desired sleep time). Twelve
of them developed stable scoliosis, whereas four continued
to have progressive course. This is the ﬁrst description of
the therapeutic application of melatonin for this disease
and suggests that melatonin supplementation could prevent
the progression of the scoliosis, especially in mild cases.
Obviously, more clinical trials are required to strengthen
on the evidence regarding the beneﬁts of melatonin and
treatment for scoliosis.
5. Concluding Remarks
From the above analyzed data, and despite some controver-
sial results which demand further clariﬁcation, the following
conclusions are proposed. (a) Melatonin seems to promote
bone formation and prevent bone resorption via several
mechanisms which include the increase in the osteoblastic
activity and diﬀerentiation, as well as the reduction in
osteoclastic diﬀerentiation and activity, and by increasing
osteoprotegerin expression and scavenging the free radicals
responsible of bone resorption. (b) Melatonin may be
an etiologic factor in the postmenopausal osteoporosis,
and a therapeutic tool for this pathology, as an adjuvant
with conventional treatments such as the administration of
estrogens. (c) The recent data concerning the association of
melatonin and AIS point toward their possible usefulness as
both a diagnostic and therapeutic tool. (d) The experimental
evidenceonanimalmodelssuggeststhevalueofclinicaltrials
to assess the therapeutic possibilities of melatonin in bone
diseases.
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